CIP2A and prostate adenocarcinoma: Interestingly, auto-antibodies against CIP2A were detected in over 30% of sera from prostate adenocarcinoma patients while only 1.5% of benign prostatic hyperplasia (BPH) patients were found to be positive for these antibodies [6].